Hyundai Bioscience Co. Ltd (048410) — Cash Flow-to-Debt Ratio
Hyundai Bioscience Co. Ltd (048410) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2026, meaning its operating cash flow of ₩-2.05 Billion could theoretically repay 0% of its total liabilities (₩17.12 Billion) in one year. See 048410 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hyundai Bioscience Co. Ltd Cash Flow-to-Debt Ratio (2008–2025)
Historical debt coverage capacity for Hyundai Bioscience Co. Ltd across 14 annual periods. For the full cash flow conversion analysis, see Hyundai Bioscience Co. Ltd (048410) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Hyundai Bioscience Co. Ltd (2008–2025)
Year-by-year debt coverage analysis for Hyundai Bioscience Co. Ltd. Check 048410 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.85x | ₩-17.05 Billion | ₩20.01 Billion | ▼ -1167.0% |
| 2024 | 0.08x | ₩2.26 Billion | ₩28.27 Billion | ▲ +110.0% |
| 2023 | -0.80x | ₩-6.01 Billion | ₩7.52 Billion | ▲ +56.1% |
| 2022 | -1.82x | ₩-16.54 Billion | ₩9.09 Billion | ▼ -6306.3% |
| 2021 | -0.03x | ₩-538.48 Million | ₩18.96 Billion | ▼ -115.6% |
| 2020 | 0.18x | ₩7.50 Billion | ₩41.09 Billion | ▼ -67.7% |
| 2019 | 0.57x | ₩9.18 Billion | ₩16.25 Billion | ▲ +52.7% |
| 2018 | 0.37x | ₩5.01 Billion | ₩13.52 Billion | ▲ +286.3% |
| 2017 | -0.20x | ₩-3.70 Billion | ₩18.61 Billion | ▼ -61.0% |
| 2016 | -0.12x | ₩-4.34 Billion | ₩35.17 Billion | ▼ -2756.0% |
| 2015 | 0.00x | ₩87.36 Million | ₩18.81 Billion | ▼ -96.1% |
| 2014 | 0.12x | ₩1.22 Billion | ₩10.32 Billion | ▼ -51.3% |
| 2011 | 0.24x | ₩3.97 Billion | ₩16.30 Billion | ▼ -12.7% |
| 2008 | 0.28x | ₩10.37 Billion | ₩37.17 Billion | — |